Related references
Note: Only part of the references are listed.SGLT2 inhibition with empagliflozin attenuates myocardial oxidative stress and fibrosis in diabetic mice heart
Chenguang Li et al.
CARDIOVASCULAR DIABETOLOGY (2019)
Myocardial Extracellular Volume Fraction Adds Prognostic Information Beyond Myocardial Replacement Fibrosis
Eric Y. Yang et al.
CIRCULATION-CARDIOVASCULAR IMAGING (2019)
Dapagliflozin Attenuates Cardiac Remodeling in Mice Model of Cardiac Pressure Overload
Lin Shi et al.
AMERICAN JOURNAL OF HYPERTENSION (2019)
Diabetic Cardiomyopathy: An Update of Mechanisms Contributing to This Clinical Entity
Guanghong Jia et al.
CIRCULATION RESEARCH (2018)
Sodium Glucose Cotransporter-2 Inhibition in Heart Failure Potential Mechanisms, Clinical Applications, and Summary of Clinical Trials
Yuliya Lytvyn et al.
CIRCULATION (2017)
Sources of variability in quantification of cardiovascular magnetic resonance infarct size - reproducibility among three core laboratories
Igor Klem et al.
JOURNAL OF CARDIOVASCULAR MAGNETIC RESONANCE (2017)
Type 2 diabetes: A 21st century epidemic
Lindsay M. Jaacks et al.
BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM (2016)
Research into the effect Of SGLT2 inhibition on left ventricular remodelling in patients with heart failure and diabetes mellitus (REFORM) trial rationale and design
Jagdeep S. S. Singh et al.
CARDIOVASCULAR DIABETOLOGY (2016)
Effect of Empagliflozin on Left Ventricular Mass and Diastolic Function in Individuals With Diabetes: An Important Clue to the EMPA-REG OUTCOME Trial?
Subodh Verma et al.
DIABETES CARE (2016)
Extracellular Volume Fraction for Characterization of Patients With Heart Failure and Preserved Ejection Fraction
Karl-Philipp Rommel et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2016)
T1 Mapping by CMR Imaging From Histological Validation to Clinical Implication
Andreas A. Kammerlander et al.
JACC-CARDIOVASCULAR IMAGING (2016)
The changing face of diabetes complications
Edward W. Gregg et al.
LANCET DIABETES & ENDOCRINOLOGY (2016)
A Multiethnic Study of Pre-Diabetes and Diabetes in LMIC
Jia Shen et al.
GLOBAL HEART (2016)
Comparison of different cardiovascular magnetic resonance sequences for native myocardial T1 mapping at 3T
Tiago Teixeira et al.
JOURNAL OF CARDIOVASCULAR MAGNETIC RESONANCE (2016)
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Bernard Zinman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Myocardial Fibrosis Quantified by Extracellular Volume Is Associated With Subsequent Hospitalization for Heart Failure, Death, or Both Across the Spectrum of Ejection Fraction and Heart Failure Stage
Erik B. Schelbert et al.
JOURNAL OF THE AMERICAN HEART ASSOCIATION (2015)
Classification and Diagnosis of Diabetes
[Anonymous]
DIABETES CARE (2015)
T1 mapping and survival in systemic light-chain amyloidosis
Sanjay M. Banypersad et al.
EUROPEAN HEART JOURNAL (2015)
2014 ACC/AHA Key Data Elements and Definitions for Cardiovascular Endpoint Events in Clinical Trials A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Data Standards ( Writing Committee to Develop Cardiovascular Endpoints Data Standards)
Karen A. Hicks et al.
CIRCULATION (2015)
Molecular mechanisms of diabetic cardiomyopathy
Heiko Bugger et al.
DIABETOLOGIA (2014)
Myocardial extracellular volume fraction quantified by cardiovascular magnetic resonance is increased in diabetes and associated with mortality and incident heart failure admission
Timothy C. Wong et al.
EUROPEAN HEART JOURNAL (2014)
Changes in Diabetes-Related Complications in the United States, 1990-2010
Edward W. Gregg et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
T1 Mapping for Characterization of Intracellular and Extracellular Myocardial Diseases in Heart Failure
Viviana Maestrini et al.
CURRENT CARDIOVASCULAR IMAGING REPORTS (2014)
2013 ACCF/AHA Guideline for the Management of Heart Failure: Executive Summary A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines
Clyde W. Yancy et al.
CIRCULATION (2013)
ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD
Lars Ryden et al.
EUROPEAN HEART JOURNAL (2013)
Fibrosis and cardiac function in obesity: a randomised controlled trial of aldosterone blockade
Wojciech Kosmala et al.
HEART (2013)
Validation of Sub-segmental Visual Scoring for the Quantification of Ischemic and Nonischemic Myocardial Fibrosis Using Late Gadolinium Enhancement MRI
Nowell M. Fine et al.
JOURNAL OF MAGNETIC RESONANCE IMAGING (2013)
Prediction of Incident Heart Failure in General Practice The Atherosclerosis Risk in Communities (ARIC) Study
Sunil K. Agarwal et al.
CIRCULATION-HEART FAILURE (2012)
Association of Imaging Markers of Myocardial Fibrosis With Metabolic and Functional Disturbances in Early Diabetic Cardiomyopathy
Christine Jellis et al.
CIRCULATION-CARDIOVASCULAR IMAGING (2011)
Contributions of inflammation and cardiac matrix metalloproteinase activity to cardiac failure in diabetic cardiomyopathy -: The role of angiotensin type 1 receptor antagonism
Dirk Westermann et al.
DIABETES (2007)
Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate
Andrew S. Levey et al.
ANNALS OF INTERNAL MEDICINE (2006)
The pathogenesis of myocardial fibrosis in the setting of diabetic cardiomyopathy
J Asbun et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2006)
Modified Look-Locker inversion recovery (MOLLI) for high-resolution T1 mapping of the heart
DR Messroghli et al.
MAGNETIC RESONANCE IN MEDICINE (2004)
Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial - the Losartan Heart Failure Survival Study ELITE II
B Pitt et al.
LANCET (2000)
Bayesian model selection and model averaging
L Wasserman
JOURNAL OF MATHEMATICAL PSYCHOLOGY (2000)
Share Paper
